title: Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
abstract: OBJECTIVE
  To report the diagnosis of acute VKH-like syndrome as a complication from dabrafenib (a serine/threonine inhibitor of BRAF V600) and trametinib (a MEK inhibitor). In combination, these targeted agents have been shown to prolong overall survival and progression free survival in BRAF mutant metastatic melanoma.
  
  
  METHODS
  Retrospective medical chart review including radiologic and ophthalmologic investigations.
  
  
  RESULTS
  A patient with metastatic melanoma being treated with dabrafenib and trametinib for 2 months presented with 1 week of visual blurring. He had developed bilateral optic disc swelling and uveitis that responded to pulsed steroid therapy.
  
  
  CONCLUSIONS
  VKH-like syndrome is a rare but serious complication of targeted therapy that should be considered when evaluating a patient with visual disturbances on dabrafenib and trametinib therapy.
authors.affiliation: a Chris O'Brien Lifehouse , Sydney , Australia.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Lim
authors.affiliation: a Chris O'Brien Lifehouse , Sydney , Australia.
authors.forename: Anna J
authors.initials: AJ
authors.lastname: Lomax
authors.affiliation: a Chris O'Brien Lifehouse , Sydney , Australia.|b Royal Prince Alfred Hospital , Sydney , Australia.
authors.forename: Catriona
authors.initials: C
authors.lastname: McNeil
authors.affiliation: b Royal Prince Alfred Hospital , Sydney , Australia.
authors.forename: Brian
authors.initials: B
authors.lastname: Harrisberg
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000150:complications* / Q000175:diagnosis / Q000556:secondary; D008875:Middle Aged; D009898:Optic Disk / Q000473:pathology*; D010091:Oximes / Q000627:therapeutic use*; D010211:Papilledema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D011728:Pyridones / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000150:complications* / Q000473:pathology; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C561627:dabrafenib
keywords: BRAF/MEK inhibitor; dabrafenib; ocular toxicity; papillitis; trametinib